公司愿景——专注于原创药全球同步开发

为重大疾病治疗提供突破性创新产品
新药研发创业者的助推器
共同成长为全球具有影响力的制药企

 

地址:北京市经济开发区科创六街88号(生物医药园)F2楼

电话:010-56315466       传真:010-56315314

邮箱:hr@jacobiopharma.com

北京加科思科新药研发有限公司     京CIP07097878    中企动力提供技术支持

Jacobio Received IND Approval for CD73 mAb JAB-BX102 from FDA

Jacobio Received IND Approval for CD73 mAb JAB-BX102 from FDA

Release time:
2021-10-15 13:15
Abstract:
Preclinical data have shown that JAB-BX102 has the advantage of dose activity and has potential to benefit patients with solid tutors.
Jacobio Pharmaceuticals Announces 2021 Interim Results

Jacobio Pharmaceuticals Announces 2021 Interim Results

Release time:
2021-09-01 00:14
Abstract:
Investment in R&D tracking for 146% YoY increase while pace of research accelerates alongside ongoing development of clinical stage assets.
Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

Jacobio Announces Strategic Investment in Hebecell to Further Develop iPSC-NK Cell Therapy

Release time:
2021-09-01 00:03
Abstract:
“With the partnership with Hebecell in place, we plan to add the allogeneic cell therapy into our pipe-lines in a move to explore the clinical value of a combination therapy with our existing products,” said Dr. Wang Yinxiang, Chairman and CEO of Jacobio.